Xeris Biopharma (XERS) Q3 2025 Earnings Transcript [Yahoo! Finance]
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Chief Executive Officer — John P. Shannon Chief Financial Officer — Steven M. Pieper Need a quote from a Motley Fool analyst? Email pr@fool.com Full Conference Call Transcript John P. Shannon: Thank you, Allison, and good morning, everyone. I am excited to share that Q3 marked another record-setting quarter for Xeris Biopharma Holdings, Inc. Total product revenue exceeded $74 million, representing a 40% increase year over year, as highlighted in this morning's press release. The strength of our year-to-date results gives us the confidence to raise the lower end of our full-year total revenue guidance. We now expect total revenue for the year to be in the range of $285 million to $290 million, a 42% increase at the midpoint. Our performance was fueled by robust patient demand across all three of our products, reflecting the tremendous value our therapies are bringing to patients and the consistent and outstanding execution of our team. Recorlev has remained the primary growt
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- What Analysts Think Is Changing The Story For Xeris Biopharma Holdings [Yahoo! Finance]Yahoo! Finance
- Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent ApplicationBusiness Wire
- Xeris Biopharma (NASDAQ:XERS) had its price target raised by analysts at Piper Sandler from $6.00 to $8.00. They now have a "neutral" rating on the stock.MarketBeat
- Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.MarketBeat
XERS
Earnings
- 11/6/25 - Miss
XERS
Sec Filings
- 12/2/25 - Form 4
- 12/1/25 - Form 8-K
- 11/17/25 - Form 4
- XERS's page on the SEC website